Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
